Mesenchymal stem cells (MSCs) induce both immune-modulatory and neurotrophic effects, and are safe when administered to patients with MS or amyotrophic lateral sclerosis (ALS). The current phase 2b double blind randomised trial, presented by Prof. Dimitrios Karussis (Hebrew University of Jerusalem, Israel), evaluated the safety and efficacy of transplantation of autologous bone marrow-derived MSCs in patients with active progressive MS. Furthermore, this study evaluated the optimal route of administration of MSCs, comparing intrathecal to intravenous administration .
This trial enrolled 48 patients with progressive MS (EDSS range: 3.5-6.5). The participants randomly received autologous MSCs or placebo via intrathecal or intravenous administration. At 6 months, treatment groups were crossed over, and patients re-treated with either MSC or placebo.
Per-protocol analysis of the pre-determined primary endpoint showed that significantly fewer patients...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Longer OS with Atezolizumab + Carboplatin + Nab-paclitaxel in Advanced Squamous NSCLC Next Article
Patient awareness about family planning represents a major knowledge gap »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.